CLINICAL PICTURE OF SINUSITIS IN PATIENTS AFTER COVID-19 WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Keywords:
sinusitis, sinusitis after covid-19, chronic obstructive pulmonary disease, resonance therapy, quality of life, vascular microcirculationAbstract
The significance of the combined pathology of the maxillary sinus and bronchi after coronavirus infection is determined not only by the prevalence and severity of the disease but also by the negative effect on the body as a whole and the low effectiveness of the treatment. One of the main directions of therapeutic measures is after coronavirus infection is the correction of the imbalance of the hemostasis system detected in such patients (Orekhova L.Yu. et al., 2020; Shapavalov V.D., 2020). In the domestic and foreign literature, there are practically no scientifically substantiated data on the possibilities of an integrated approach to systemic methods of treating chronic sinusitis after suffering from covid-19 (CG - PC), combined with chronic obstructive pulmonary disease and bronchial asthma, which is due to the functional and industrial disunity of dentists with doctors’ other specialties.
References
Alyavi AL, Rakhimova DA, Sadykova GA Clinical and functional state in patients with chronic obstructive pulmonary disease at different degrees of pulmonary heart severity. III Congress of Thoracic Society of Kyrgyzstan.Bishkek, 2011: 83.
Alyavi A.L., Rakhimova D.A., Sadykova G.A. Clinical and experimental aspects of ozone therapy. Uzbekistan therapy ahborot-nomasi. Tashkent, 2015; 4: 74-78.
Baevsky R.M., Ivanov G.G. To the question of formalization of conclusions on the results of analysis of psychological approach to HRV. // Functional diagnostics. 2016. №2. 89-94
Chuchalin A.G. Chronic obstructive pulmonary disease and associated diseases. М.-2018. 25p.
Global initiative for chronic obstructive ling disease. Global strategy for the diagnosis, management and prevention of chronic obstruktive pulmonary disease. NHLBI / WHO workshop report. Bethesda: National Heart, Lung and Blood institute: update 2016 (W Wgoldcopd. com).
Calverley P.M., Walker P. Chronic obstructive pulmonary disease. //Lancet.-2016.-vol.362.-p.1053-1061.
Peiffer,C.J., B. Poline, L. Thivard, M. Aubier, Y. Samson. Neural substrates for the perception of acutely induced dyspnea. Am J Respir Crit Care Med. 2016.163(4):951–72
Rakhimova D.A., Kasimova, G.M. Estimating psychovegetative factors of regulation in patients with chronic obstructive pulmonale diseases. «Journal of life-sciences». Argentina, 2012; 4: 457-461.
Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels to mark metabolic and functional impairment in advanced COPD // Thorax. -2006. -Vol.61. - P.17-22.
Burgel PR, Paillasseur JL, Peene B, et al. Two distinct chronic obstructive pulmonary diseases (COPD) phenotypes are associated with a high risk of mortality // PLoS One. -2012. -Vol.7. - P.e51048.
Celli B.R., Macnee W. Сommittee members. standarts for diagnosing and treating patients with COPD: a summary of the ATS / ERS-Position paper // Eur. Respuir. J. -2004. -Vol. 23(6). - P.932-946.
Obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients // Ann. Epidemiol. -2006.-Vol.16. -P.63-70.
Hurd S. S., Lenfant C. COPD: good lung health is the key. Comment // Lancet.- 2005.- V.366. -P.1832–1834.
Mannino D.M., Buist A.S. Global burden of COPD: risk factors, prevalence, and future trends // Lancert. -2007. -Vol.370. -P.765-773.
Metabolic syndrome and its effects in COPD patients/ Memis U., Sagcan G., Engin R. et al.// The Toraks Dergisi: Abst.Turkish Thoracic Society.- 2009.-MS024.-162s.
Report GOLD: Global initiative for chronic obstructive lung disease, update 2008, available on www.goldcopd.org
